scholarly journals Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Umair Majeed ◽  
Rami Manochakian ◽  
Yujie Zhao ◽  
Yanyan Lou
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Small Cell ◽  
Small Cell Lung ◽  
Common Variety ◽  
Immunohistochemical Techniques

AbstractLung cancer remains the leading cause of cancer-related mortality in both men and women in the US and worldwide. Non-small cell lung cancer is the most common variety accounting for 84% of the cases. For a subset of patients with actionable mutations, targeted therapy continues to provide durable responses. Advances in molecular and immunohistochemical techniques have made it possible to usher lung cancer into the era of personalized medicine, with the patient getting individualized treatment based on these markers. This review summarizes the recent advances in advanced NSCLC targeted therapy, focusing on first-in-human and early phase I/II clinical trials in patients with advanced disease. We have divided our discussion into different topics based on these agents' mechanisms of action. This article is aimed to be the most current review of available and upcoming targeted NSCLC treatment options. We will also summarize the currently available phase I/II clinical trial for NSCLC patients at the end of each section.

A phase I/II study of antibody targeted therapy with CDP671/1 in advanced non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 53
Author(s):  
P Lorigan ◽  
J Carmichael ◽  
P.J Woll ◽  
K O'Byrne ◽  
S Browne ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

2020 ◽  
Vol 25 ◽  
pp. 61-66
Author(s):  
Gerard M. Walls ◽  
Jamie B. Oughton ◽  
Anthony J. Chalmers ◽  
Sarah Brown ◽  
Fiona Collinson ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Novel Agents ◽  
Small Cell Lung ◽  
Conventional Radiotherapy

scholarly journals Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Walter Z. Wang ◽  
Konstantin Shilo ◽  
Joseph M. Amann ◽  
Alyssa Shulman ◽  
Mohammad Hojjat-Farsangi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Small Cell ◽  
Orphan Receptor ◽  
Small Cell Lung ◽  
Sclc Patient

AbstractSmall cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52/56) and 86% (48/56) of SCLC patient samples, respectively. Similarly, ROR1 and BCL2 were shown by qRT-PCR to have elevated expression in 79% (22/28) and 100% (28/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500 nM or less. Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

scholarly journals P2.03a-028 Phase I/II Trial of Carboplatin, nab-Paclitaxel and Bevacizumab for Advanced Non-Squamous Non-Small Cell Lung Cancer: Results of Phase I Part

2017 ◽  
Vol 12 (1) ◽  
pp. S905
Author(s):  
Satoshi Ikeo ◽  
Naoyuki Nogami ◽  
Hiromoto Kitajima ◽  
Hiroshige Yoshioka ◽  
Akihiro Bessho ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Phase I and pharmacokinetic (PK) study of Nedaplatin (254-S) in elderly patients with advanced non-small cell lung cancer (NSCLC)

Lung Cancer ◽  
2000 ◽  
Vol 29 (1) ◽  
pp. 69 ◽  
Author(s):  
T Kurata ◽  
T Tamura ◽  
N Yamamoto ◽  
I Sekine ◽  
H Kunitoh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patients ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

Phase I Study of Weekly Alternating Therapy with Irinotecan/Cisplatin and Etoposide/Cisplatin for Patients with Small-Cell Lung Cancer

2003 ◽  
Vol 5 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Faye M. Johnson ◽  
Jonathan M. Kurie ◽  
Beverly O. Peeples ◽  
J. Jack Lee ◽  
Lei Feng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Phase I ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase I Study ◽  
Small Cell ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document